Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arbutus Biopharma

ContraFect

Eiger BioPharmaceuticals

IVERIC bio Inc

Pfizer

SQZ Biotechnologies

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out

Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.

Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year

Keurig Dr Pepper Inc

Stanley Black & Decker

Check these dividend stocks out for your watchlist right now.

4 Top Dividend Stocks To Watch In The Stock Market Today

Eli Lilly and Company (NYSE:LLY ) 82nd Scientific Sessions of the American Diabetes Association conference June 7, 2022 11:30 AM ET Company Participants Lauren Zierke - Senior Director of Investor Relations Mike Mason - President of Lilly Diabetes Jeff Emmick - Vice President of Diabetes Product Development Ruth Gimeno - Vice President of Diabetes Research & Clinical Investigation Conference Call Participants Seamus Fernandez - Guggenheim Chris Schott - JPMorgan Steve Scala - Cowen Geoff Meacham - Bank of America David Risinger - SVB Securities Tim Anderson - Wolfe Research Mike DiFiore - Evercore ISI Vamil Divan - Mizuho Securities Andrew Baum - Citi Chris Shibutani - Goldman Sachs Kerry Holford - Berenberg Nishant Gandhi - Truist Securities Evan Seigerman - BMO Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the ADA Investor Update.

Eli Lilly and Company (LLY) Management Presents at 82nd Scientific Sessions of the American Diabetes Association conference (Transcript)

(Reuters) -A former human resources officer at Eli Lilly and Co sued the drugmaker on Monday, alleging she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs.

Whistleblower sues Eli Lilly over drug manufacturing problems

80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed Data supported both once every two week and once every four week maintenance dosing, with consistent and durable responses INDIANAPOLIS , June 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company's investigational IL-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 clinical trials (ADvocate 1 and 2) showed eight out of ten patients who achieved clinical response (EASI-75*) with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with the once every two weeks or four weeks regimen.

Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials

Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study Exploratory analysis showed that Mounjaro achieved A1C and weight targets in less time than injectable semaglutide 1 mg or titrated insulin degludec INDIANAPOLIS , June 6, 2022 /PRNewswire/ -- New data from a mechanism of action study and new analyses of the global registration program for Eli Lilly and Company's (NYSE: LLY) Mounjaro™ (tirzepatide) injection were presented at the American Diabetes Association's® (ADA) 82nd Scientific Sessions®, adding to the robust body of data about Mounjaro for the treatment of adults with type 2 diabetes. More than 20 presentations on Mounjaro were accepted for disclosure at the ADA's Scientific Sessions.

New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®

Salesforce

SVB Financial Group

Recent moves within the market have absolutely crushed equities to bear market status.

3 Big Ideas From JP Morgan With Up to Nearly 80% Upside

Eli Lilly & Co (NYSE:LLY) is in the spotlight, after the pharmaceutical concern reported strong data from studies involving diabetes drugs Trulicity and Jardiance.

Eli Lilly Stock Rises on Upbeat Drug Data

Jardiance showed a reduction in relative risk of all-cause mortality by 40% compared with DPP-4 inhibitors in the subset of people with Medicare coverage Data from these final analyses of EMPRISE complements findings from the landmark EMPA-REG OUTCOME® trial RIDGEFIELD, Conn. and INDIANAPOLIS , June 5, 2022 /PRNewswire/ -- Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that Jardiance® (empagliflozin) was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adults with type 2 diabetes in routine care.

Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study

Apple

2 Top Stocks to Buy With $500

AWARD-PEDS results presented at ADA's 82nd Scientific Sessions® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population INDIANAPOLIS , June 4, 2022 /PRNewswire/ -- In the phase 3 AWARD-PEDS clinical trial from Eli Lilly and Company (NYSE: LLY), Trulicity® (dulaglutide) (at 0.75 mg and 1.5 mg doses) led to superior A1C reductions at 26 weeks versus placebo in youth and adolescents (ages 10 to 17 years old) with type 2 diabetes inadequately controlled with diet and exercise, with or without metformin and/or basal insulin. The study, presented in a poster at the American Diabetes Association's® (ADA) 82nd Scientific Sessions and simultaneously published in the New England Journal of Medicine , met all of its primary and secondary glycemic control objectives: percent of patients achieving A1C of

Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo

Detailed results from Lilly's first phase 3 trial in obesity or overweight presented at the American Diabetes Association's ®  82nd Scientific Sessions ®  and simultaneously published in NEJM INDIANAPOLIS, June 4, 2022 /PRNewswire/ -- Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-1 clinical trial evaluating tirzepatide for the treatment of obesity or overweight were simultaneously published today in The New England Journal of Medicine (NEJM) and presented in a symposium sponsored by the American Diabetes Association® (ADA) during the ADA's 82nd Scientific Sessions®. Tirzepatide met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimandsi.

Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight

Shares of Eli Lilly & Co. LLY, -4.05% fell 4.0% in afternoon trading Tuesday, to pullback from the previous session's record close, after the drug maker disclosed that its largest shareholder sold nearly $64 million worth of its shares. In a Form 4 filing with the Securities and Exchange Commission, the company said Lilly Endowment Inc., a private philanthropic foundation, sold 200,000 Eli Lilly shares in the open market on May 27.

Eli Lilly stock pulls back from record high after disclosing sales by largest shareholder

AbbVie

Their strong underlying businesses should keep the quarterly payouts flowing to shareholders.

3 Dividend Stocks You Can Buy and Hold Forever

INDIANAPOLIS , May 26, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022. The data include new analyses from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a selective RET inhibitor), and imlunestrant (an investigational, oral selective estrogen receptor degrader [SERD]).

Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Bristol-Myers

Protagonist Therapeutics

Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.

A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?

Eli Lilly & Co. Inc. LLY, +0.26% said Wednesday that it plans to invest $2.1 billion in two new manufacturing sites in Indiana. The proposed sites are expected to create 500 jobs for Lilly workers.

Lilly proposes two new manufacturing sites in Indiana

INDIANAPOLIS , May 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County. These new facilities will expand Lilly's manufacturing network for active ingredients and new therapeutic modalities, such as genetic medicines, and represent the company's dedication to strengthening its portfolio of potentially life-changing treatments.

Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana

AstraZeneca

Share buybacks and dividends among large drug makers reached a five-year high in 2021 as spending climbed to about $110 billion, according to an analysis by pharma consulting group Evaluate Vantage.

Eli Lilly and AstraZeneca Are the Lowest Spenders on Dividends, Buybacks

Eli Lilly and AstraZeneca Lowest Spenders on Dividends, Buybacks

Eli Lilly and Company (NYSE:LLY ) UBS Global Healthcare Conference May 24, 2022 8:30 AM ET Company Participants Mike Mason - President of Lilly Diabetes Conference Call Participants Colin Bristow - UBS Colin Bristow Good morning, everyone, and welcome to day two of the UBS Global Healthcare Conference. I'm Colin Bristow one of the biotech pharma analysts here at UBS.

Eli Lilly and Company (LLY) Management Presents at UBS Global Healthcare Conference (Transcript)

It could mean billions in revenue for the company.

Why This FDA Approval Is a Game Changer for Eli Lilly

Nearly all mirikizumab-treated patients who achieved clinical remission at one year were not taking steroids INDIANAPOLIS , May 24, 2022 /PRNewswire/ -- In Eli Lilly and Company's (NYSE:LLY) pivotal, Phase 3 LUCENT-2 study, patients with ulcerative colitis (UC) who responded to mirikizumab at 12 weeks achieved and maintained statistically superior and clinically meaningful improvements at one year compared to placebo across the primary endpoint of clinical remission and all key secondary endpoints, including bowel urgency severity, using a novel, patient-reported outcome measure. Late-breaking results are being presented today at Digestive Disease Week (DDW).

Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study

INDIANAPOLIS , May 23, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's 82nd Scientific Sessions. The webcast will begin at 11:30 a.m.

News for Eli Lilly Stock (LLY)